This study applied a multi-criteria decision analysis (MCDA) to assess the value of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer in Catalonia. The combination demonstrated a positive value contribution versus available alternatives, primarily driven by overall survival, safety and clinical efficacy outcomes.
